QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-q1-eps-009-misses-008-estimate-sales-7300k-miss-12000k-estimate

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.

 clene-highlights-presentation-of-phase-2-visionary-ms-trial-data-at-2024-american-academy-of-neurology-annual-meeting-says-long-term-cnm-au8-treatment-encompassing-up-to-three-years-was-well-tolerated-no-significant-safety-findings-were-observed

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remye...

 benchmark-reiterates-buy-on-clene-maintains-5-price-target

Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.

 clene-announces-peer-reviewed-publication-characterizing-protein-corona-of-investigational-neurodegenerative-disease-drug-cnm-au8

Proprietary catalytic gold nanocrystals comprising Clene's investigational drug CNM-Au8® develop a protein corona upon expo...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-q4-earnings-insights
Clene: Q4 Earnings Insights
03/13/2024 13:40:06

 clene-fy-gaap-eps-047-misses-046-estimate-sales-65400k-beat-55700k-estimate

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2....

 hc-wainwright--co-maintains-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-presents-clinical-results-of-cnm-au8-30mg-treatment-from-visionary-ms-trial-long-term-extension-at-annual-actrims-forum-2024

Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contras...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION